The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback